全文获取类型
收费全文 | 1336014篇 |
免费 | 96247篇 |
国内免费 | 2916篇 |
专业分类
耳鼻咽喉 | 19741篇 |
儿科学 | 40362篇 |
妇产科学 | 38714篇 |
基础医学 | 187631篇 |
口腔科学 | 39907篇 |
临床医学 | 112596篇 |
内科学 | 262075篇 |
皮肤病学 | 30370篇 |
神经病学 | 106980篇 |
特种医学 | 53923篇 |
外国民族医学 | 435篇 |
外科学 | 208147篇 |
综合类 | 31036篇 |
现状与发展 | 6篇 |
一般理论 | 437篇 |
预防医学 | 92070篇 |
眼科学 | 31434篇 |
药学 | 100389篇 |
2篇 | |
中国医学 | 2999篇 |
肿瘤学 | 75923篇 |
出版年
2018年 | 11866篇 |
2015年 | 12046篇 |
2014年 | 16877篇 |
2013年 | 25496篇 |
2012年 | 33426篇 |
2011年 | 35280篇 |
2010年 | 20992篇 |
2009年 | 20468篇 |
2008年 | 33944篇 |
2007年 | 37026篇 |
2006年 | 37594篇 |
2005年 | 36357篇 |
2004年 | 35380篇 |
2003年 | 34351篇 |
2002年 | 33869篇 |
2001年 | 63655篇 |
2000年 | 65361篇 |
1999年 | 55446篇 |
1998年 | 14728篇 |
1997年 | 13516篇 |
1996年 | 12986篇 |
1995年 | 12260篇 |
1994年 | 11494篇 |
1992年 | 42707篇 |
1991年 | 41274篇 |
1990年 | 40541篇 |
1989年 | 39535篇 |
1988年 | 36937篇 |
1987年 | 36399篇 |
1986年 | 34879篇 |
1985年 | 33096篇 |
1984年 | 24787篇 |
1983年 | 20984篇 |
1982年 | 12609篇 |
1981年 | 11507篇 |
1980年 | 10709篇 |
1979年 | 23861篇 |
1978年 | 17017篇 |
1977年 | 14760篇 |
1976年 | 13331篇 |
1975年 | 15218篇 |
1974年 | 18042篇 |
1973年 | 17535篇 |
1972年 | 16789篇 |
1971年 | 15694篇 |
1970年 | 14874篇 |
1969年 | 14321篇 |
1968年 | 13440篇 |
1967年 | 11990篇 |
1966年 | 11241篇 |
排序方式: 共有10000条查询结果,搜索用时 517 毫秒
51.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献
52.
53.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献
54.
Erin C. Tully Jackson M. Gray Sherryl H. Goodman Stephen Nowicki Jr. 《Early child development and care》2016,186(12):1939-1951
Children who expect they can bring about good outcomes and avoid bad outcomes tend to experience more personal successes. Little is known about factors that contribute to these ‘control expectancies’. The purpose of the present study was to determine whether children's internal control expectancies occur in the context of parents’ internal control expectancies, low family strain, and high family cohesiveness and whether these factors are more strongly related to daughters’ than sons’ control expectancies. A community sample of 85 children aged 9–11 years and their parents (85 mothers; 63 fathers) completed rating scales. Fathers’ more internal control expectancies and mothers’ reports of fewer family strains were associated with daughters’ but not sons’ greater internal control expectancies, and greater family cohesiveness was related to both daughters’ and sons’ internal control orientations. These findings suggest that family factors may contribute to children's, particularly daughters’, development of internal control expectancies. 相似文献
55.
56.
57.
58.
59.
60.